Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 81

recruiting
3 977
countries
28
conditions
2 105

1 282 trials match your criteria

Study of palbociclib with hormone therapy versus hormone therapy alone in patients with recurrent hormone receptor-positive/HER2-negative breast cancer after surgery

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib

Study on the Safety and Effectiveness of Rilzabrutinib for Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia (ITP)

Investigational
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rilzabrutinib

Hypertension

Not recruiting

Study on Baxdrostat for Lowering Blood Pressure in Patients with Resistant Hypertension

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat

Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide

Plasma cell myeloma

Not recruiting

Study Comparing Elranatamab and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab

Polycythaemia vera

Not recruiting

Study on the Effects of Rusfertide (PTG-300) for Patients with Polycythemia Vera

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Rusfertide

Plasma cell myeloma

Not recruiting

Study Comparing Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel for Newly Diagnosed Multiple Myeloma Patients Not Planning Stem Cell Transplant

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Ponsegromab

Plasma cell myeloma

Not recruiting

Study on Alnuctamab and Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Alnuctamab

Rheumatoid arthritis

Not recruiting

Study on Burfiralimab for Patients with Moderate to Severe Rheumatoid Arthritis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Burfiralimab

Study of VRDN-001 for Patients with Thyroid Eye Disease Who Did Not Respond to Previous Treatment

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.